FDA slaps Henan Lihua Pharmaceutical with warning letter

fda
The FDA found data integrity issues during inspections of two plants operated by Henan Lihua Pharmaceutical. (FDA)

A Chinese API maker that was put on the FDA’s import alert list in March has now been given a warning letter outlining data integrity issues that raise questions about the quality of its drugs.

The letter was issued June 12 to Henan Lihua Pharmaceutical, which specializes in production of corticosteroids APIs and related intermediates. The citation followed inspections of the company’s two plants in Anyang late last year.

What concerned FDA inspectors was the fact that the company’s quality control unit was not approving the release of all of the company’s products, and the fact that it didn't have control over some of its documents. In addition to that, the company was not keeping a complete audit trail of its analytical testing.

The FDA noted that that Henan Lihua Pharmaceutical “committed to using a consultant to assist in meeting FDA requirements,” then gave the drugmaker a long list of improvements in data integrity that must be made if it wants to free itself from the import alert.

RELATED: FDA warning thrashes Indian drugmaker for filthy plant, data falsification

Data integrity has become a big consideration of the FDA, which has often found foreign drugmakers falsifying testing data that show their drugs are safe.

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.